Further studies are clearly required to fully understand whether CX3CL1 expression may help define patient risk and aid in distinguishing between susceptibility to molecular tumor subtypes during early cancer development before histological abnormalities are detected. The gene discussed is CX3CL1; the disease is neoplasm.